Pan-genome and resistome analysis of extended-spectrum ß-lactamase-producing Escherichia coli: A multi-setting epidemiological surveillance study from Malaysia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
08
2021
accepted:
23
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
4
5
2022
Statut:
epublish
Résumé
This study profiled the prevalence of extended-spectrum ß-lactamase-producing Escherichia coli (ESBL-EC) in the community and compared their resistome and genomic profiles with isolates from clinical patients through whole-genome sequencing. Fecal samples from 233 community dwellers from Segamat, a town in southern Malaysia, were obtained between May through August 2018. Putative ESBL strains were screened and tested using antibiotic susceptibility tests. Additionally, eight clinical ESBL-EC were obtained from a hospital in the same district between June through October 2020. Whole-genome sequencing was then conducted on selected ESBL-EC from both settings (n = 40) for pan-genome comparison, cluster analysis, and resistome profiling. A mean ESBL-EC carriage rate of 17.82% (95% CI: 10.48%- 24.11%) was observed in the community and was consistent across demographic factors. Whole-genome sequences of the ESBL-EC (n = 40) enabled the detection of multiple plasmid replicon groups (n = 28), resistance genes (n = 34) and virulence factors (n = 335), with no significant difference in the number of genes carried between the community and clinical isolates (plasmid replicon groups, p = 0.13; resistance genes, p = 0.47; virulence factors, p = 0.94). Virulence gene marker analysis detected the presence of extraintestinal pathogenic E. coli (ExPEC), uropathogenic E. coli (UPEC), and enteroaggregative E. coli (EAEC) in both the community and clinical isolates. Multiple blaCTX-M variants were observed, dominated by blaCTX-M-27 (n = 12), blaCTX-M-65 (n = 10), and blaCTX-M-15 (n = 9). The clinical and community isolates did not cluster together based on the pan-genome comparison, suggesting isolates from the two settings were clonally unrelated. However, cluster analysis based on carried plasmids, resistance genes and phenotypic susceptibility profiles identified four distinct clusters, with similar patterns between the community and clinical isolates. ESBL-EC from the clinical and community settings shared similar resistome profiles, suggesting the frequent exchange of genetic materials through horizontal gene transfer.
Identifiants
pubmed: 35271656
doi: 10.1371/journal.pone.0265142
pii: PONE-D-21-27273
pmc: PMC8912130
doi:
Substances chimiques
Anti-Bacterial Agents
0
Virulence Factors
0
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0265142Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Microbiol Rev. 2014 Jul;27(3):543-74
pubmed: 24982321
PLoS One. 2013 Oct 17;8(10):e77968
pubmed: 24147104
PLoS One. 2017 May 30;12(5):e0178623
pubmed: 28558003
Clin Infect Dis. 2016 Oct 1;63(7):896-903
pubmed: 27358356
Front Microbiol. 2017 Feb 03;8:146
pubmed: 28217123
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
Int J Antimicrob Agents. 2010 Nov;36(5):408-14
pubmed: 20728316
Eur J Clin Microbiol Infect Dis. 2012 May;31(5):821-4
pubmed: 21894534
J Antimicrob Chemother. 2021 Jan 1;76(1):22-29
pubmed: 33305801
J Biomed Biotechnol. 2009;2009:165637
pubmed: 19672454
Genome Med. 2014 Nov 20;6(11):90
pubmed: 25422674
Malays J Med Sci. 2013 May;20(3):14-22
pubmed: 23966820
Jpn J Infect Dis. 2012;65(5):433-5
pubmed: 22996219
Lancet Infect Dis. 2019 Dec;19(12):1325-1335
pubmed: 31653524
Bioinformatics. 2015 Nov 15;31(22):3691-3
pubmed: 26198102
Bioinformatics. 2018 Jan 15;34(2):292-293
pubmed: 29028899
Biomed Res Int. 2014;2014:601630
pubmed: 24860827
J Antimicrob Chemother. 2012 Dec;67(12):2793-803
pubmed: 22915465
J Antimicrob Chemother. 2020 Feb 1;75(2):342-350
pubmed: 31711228
Int J Antimicrob Agents. 2018 Feb;51(2):181-189
pubmed: 28993143
Int J Epidemiol. 2017 Oct 1;46(5):1370-1371g
pubmed: 29024948
Front Microbiol. 2020 Feb 21;11:108
pubmed: 32153519
Nat Microbiol. 2018 Sep;3(9):1063-1073
pubmed: 30127495
Bioinformatics. 2019 Feb 1;35(3):526-528
pubmed: 30016406
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
J Glob Antimicrob Resist. 2020 Jun;21:229-234
pubmed: 31726236
BMJ. 2017 Sep 5;358:j2291
pubmed: 28874360
Curr Protoc Bioinformatics. 2020 Mar;69(1):e96
pubmed: 32162851
Sci Rep. 2021 Jan 22;11(1):2091
pubmed: 33483551
Int Microbiol. 2021 May;24(2):243-250
pubmed: 33469786
mSphere. 2019 May 22;4(3):
pubmed: 31118304
BMJ Open. 2019 Mar 5;9(3):e023859
pubmed: 30842108
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Microb Drug Resist. 2012 Aug;18(4):408-16
pubmed: 22394084
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595
pubmed: 28594827
Clin Microbiol Infect. 2021 Sep;27(9):1322-1329
pubmed: 33421572
Sci Rep. 2019 Sep 13;9(1):13245
pubmed: 31519972
Antimicrob Resist Infect Control. 2017 Nov 15;6:118
pubmed: 29167743
Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):2057-60
pubmed: 22271302
Clin Infect Dis. 2009 Sep 1;49(5):682-90
pubmed: 19622043
Front Microbiol. 2019 Aug 02;10:1797
pubmed: 31428078
J Clin Microbiol. 2009 Nov;47(11):3780-2
pubmed: 19741070
Int J Antimicrob Agents. 2019 Oct;54(4):381-399
pubmed: 31369812
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
S Afr Med J. 2019 Dec 12;110(1):49-54
pubmed: 31865943
Microb Drug Resist. 2018 May;24(4):367-376
pubmed: 29727265
J Travel Med. 2016 Feb 08;23(2):tav024
pubmed: 26858272
Antimicrob Agents Chemother. 2012 Sep;56(9):4703-6
pubmed: 22710119
Clin Microbiol Rev. 2009 Jan;22(1):161-82, Table of Contents
pubmed: 19136439
Methods Mol Biol. 2019;1962:227-245
pubmed: 31020564
J Antimicrob Chemother. 2020 Dec 1;75(12):3491-3500
pubmed: 32780112
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
PLoS Pathog. 2021 Oct 15;17(10):e1010005
pubmed: 34653218
J Antimicrob Chemother. 2010 May;65(5):859-65
pubmed: 20233775
Emerg Infect Dis. 2008 Feb;14(2):195-200
pubmed: 18258110
Nat Commun. 2017 Nov 22;8(1):1689
pubmed: 29162798
BMC Infect Dis. 2019 Nov 21;19(1):979
pubmed: 31752702
PLoS One. 2013;8(2):e57794
pubmed: 23460907
Antimicrob Agents Chemother. 2003 Jul;47(7):2161-8
pubmed: 12821463
Sci Rep. 2021 Jan 29;11(1):2618
pubmed: 33514807
Appl Environ Microbiol. 2013 May;79(9):3021-6
pubmed: 23455339
Jpn J Infect Dis. 2010 Sep;63(5):317-22
pubmed: 20858996
Front Microbiol. 2015 Mar 27;6:239
pubmed: 25870591
J Bacteriol. 2007 May;189(9):3532-46
pubmed: 17351047
Microb Drug Resist. 2019 Sep;25(7):1087-1098
pubmed: 30844323
Molecules. 2017 Dec 19;22(12):
pubmed: 29257114
Antimicrob Resist Infect Control. 2020 Aug 21;9(1):139
pubmed: 32825851
Antimicrob Agents Chemother. 2003 Aug;47(8):2565-71
pubmed: 12878520
BMC Infect Dis. 2017 Jan 5;17(1):26
pubmed: 28056827
Antimicrob Agents Chemother. 2005 Jul;49(7):3001-3
pubmed: 15980384
Int J Med Microbiol. 2020 Jan;310(1):151377
pubmed: 31757694
J Antimicrob Chemother. 2017 Jan;72(1):166-171
pubmed: 27703058
Microorganisms. 2020 Jun 30;8(7):
pubmed: 32629840
BMC Public Health. 2016 Aug 02;16:699
pubmed: 27484086
PLoS One. 2015 Jul 23;10(7):e0133654
pubmed: 26203651
mSphere. 2019 Jul 3;4(4):
pubmed: 31270174
Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):69-75
pubmed: 28918585
Ann Clin Microbiol Antimicrob. 2017 Jan 6;16(1):1
pubmed: 28061852
Microb Genom. 2020 Jul;6(7):
pubmed: 32589571
Clin Microbiol Infect. 2005 Jan;11(1):71-3
pubmed: 15649309
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063
FEMS Microbiol Ecol. 2016 Jan;92(1):
pubmed: 26656065
Lancet Infect Dis. 2018 Sep;18(9):e288-e294
pubmed: 29673734
J Infect. 2020 Aug;81(2):242-247
pubmed: 32447008
BMC Microbiol. 2011 Jun 21;11:142
pubmed: 21689465